Intralesional immunotherapy with tuberculin purified protein derivative (PPD) in recalcitrant wart: a randomized, placebo-controlled, double-blind clinical trial including …
Background: Due to paucity of randomized clinical trials, intralesional immunotherapy has
not been yet accepted as a standard therapeutic method. Objective: To examine the efficacy …
not been yet accepted as a standard therapeutic method. Objective: To examine the efficacy …
Intralesional immunotherapy with tuberculin purified protein derivative (PPD) in recalcitrant wart: A randomized, placebo-controlled, double-blind clinical trial including …
M Amirnia, E Khodaeiani, DF Fouladi… - Journal of …, 2016 - hero.epa.gov
BACKGROUND: Due to paucity of randomized clinical trials, intralesional immunotherapy
has not been yet accepted as a standard therapeutic method. OBJECTIVE: To examine the …
has not been yet accepted as a standard therapeutic method. OBJECTIVE: To examine the …
Intralesional immunotherapy with tuberculin purified protein derivative (PPD) in recalcitrant wart: A randomized, placebo-controlled, double-blind clinical trial including …
M Amirnia, E Khodaeiani, DF Fouladi… - The Journal of …, 2015 - europepmc.org
Background Due to paucity of randomized clinical trials, intralesional immunotherapy has
not been yet accepted as a standard therapeutic method. Objective To examine the efficacy …
not been yet accepted as a standard therapeutic method. Objective To examine the efficacy …
Intralesional immunotherapy with tuberculin purified protein derivative (PPD) in recalcitrant wart: A randomized, placebo-controlled, double-blind clinical trial including …
M Amirnia, E Khodaeiani, DF Fouladi, S Masoudnia - 2016 - pubmed.ncbi.nlm.nih.gov
Background Due to paucity of randomized clinical trials, intralesional immunotherapy has
not been yet accepted as a standard therapeutic method. Objective To examine the efficacy …
not been yet accepted as a standard therapeutic method. Objective To examine the efficacy …